(UroToday.com) There have been significant advances in the delivery of prostate radiotherapy in the past decade, particularly with the use of image guidance. However, in spite of this acute and late genitourinary (GU) and gastrointestinal (GI) toxicities remain a significant issue. For patients undergoing combined high-dose rate (HDR) brachytherapy and external beam radiotherapy (EBRT), there is no consensus on the timing of these treatments with significant variation between institutions. Thus, in the Poster Highlights: Prostate Cancer – Localized Disease Session at the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Imtiaz Ahmed and colleagues assessed the incidence of GI and GU toxicities in patients receiving HDR brachytherapy before and after EBRT.